Prospective study using a modified Montgomery-Asberg Depression Scale;Einsatz einer modifizierten MADRS bei depressiven patienten in einer prospektiven kohortenstudie

Nervenarzt

Volumn 78, Issue 6, 2007, Pages 685-690

  Moller H J ^a   Schnitker, J ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Institut für Angewandte Statistik IAS   (Germany)

Author keywords

Escitalopram; Montgomery Asberg Depression Scale; Observational study; Short version

Indexed keywords

ESCITALOPRAM;

ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CORRELATION ANALYSIS; DEPRESSION; DIAGNOSTIC VALUE; DISEASE SEVERITY; HUMAN; MAJOR CLINICAL STUDY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; RATING SCALE; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; COHORT STUDIES; DEPRESSIVE DISORDER; FOLLOW-UP STUDIES; HUMANS; PERSONALITY ASSESSMENT; PROSPECTIVE STUDIES; PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS;

EID: 34548385672     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-007-2278-0     Document Type: Article

References (16)

1. Auquier P, Robitail S, Llorca P, Rive B (2003) Comparison of escitalopram and citalopram efficacy: A meta-analysis. Int J Psychiatry Clin Pract 7: 259-268
2. Angst J, Bech P, Boyer P et al. (1989) Consensus conference on the methodology of clinical trials of antidepressants. Zurich, March 1988. Report of the Consensus Committee. Pharmacopsychiatry 22: 3-7
3. Benazzi F (2001) Factor analysis of the Montgomery Åsberg Depression Rating Scale in 251 bipolar II and 306 unipolar depressed outpatients. Prog Neuropsychopharmacol Biol Psychiat 25: 1369-1376
4. Bent-Hansen J, Lunde M, Klysner R et al. (2003) The validity of the depression rating scales in discriminating between citalopram and placebo in depression recurrence in the maintenance therapy of elderly unipolar patients with major depression. Pharmacopsychiatry 36: 313-316
5. Collegium Internationale Psychiatricae Scalarum (Hrsg) (2005) Internazionale Skalen für Psichiatrie. 5. vollständig überarbeitete Aufl. Beltz Test, Göttingen
6. CPMP (eds) (2002) Note for guidance on clinical investigation of medical products in the treatment of depression. The European Agency for the Evaluation of Medical Products
7. Craighead WE, Evans DD (1996) Factor analysis of the Montgomery- Åsberg Depression Rating Scale. Depression 4: 31-36
8. Galinowski A, Lehert P (1995) Structural validity of MADRS during antidepressant treatment. Int Clin Psychopharmacol 10: 157-161
9. Khan A, Khan S, Shankles E, Polissar N (2002) Relative sensitivity of the Montgomery-Åsberg Depression Rating Scale and the clinical global impressions rating scale in antidepressant clinical trials. Int Clin Psychopharmacol 17: 282-285
10. Llorca P, Azorin J, Despiegel N, Verpillat P (2005) Efficacy of escitalopram in patients with severe depression: A pooled analysis. Int J Clin Pract 59: 268-375
11. Möller HJ, Langer S, Schmauß M (2007) Escitalopram in clinical practice: Results of an open-label trial in a naturalistic setting in Germany. Pharmacopsychiatry 40: 53-57
12. Montgomery SA, Åsberg M (1979) A new depression rating scale designed to be sensitive to change. Br J Psychiatry 134: 382-389
13. Neumann NU, Schulte RM (1988) Montgomery-Åsberg-Depressions-Rating- Skala Bestimmung der Validität und Interrater-Reliabilität der deutschen Fassung. Psycho 14: 911-924
14. Parker RD, Flint EP, Bosworth HB et al. (2003) A three-factor analytic model of the MADRS in geriatric depression. Int J Geriatr Psychiatry 18: 73-77
15. Schmidtke A, Fleckenstein P, Moises W, Beckmann H (1988) Untersuchungen zur Reliabilität und Validität einer deutschen Version der Montgomery-Åsberg-Depression-Rating-Scale (MADRS). Schweiz Arch Neurol Psychiatr 139: 51-65
16. Hammond M (1998) Rating depression severity in the elderly physically ill patient: Reliability and factor structure of the Hamilton and the Montgomery-Åsberg Depression Rating Scales. Int J Geriatr Psychiatry 13: 257-261